The Development Course of Yuheng Pharmaceutical Industry

Yuheng Pharmaceutical Co., Ltd. is a pharmaceutical enterprise dedicated to scientific research and development, pharmaceutical production and commercial circulation. The company is located in Harbin Limin Development Zone Medicine Science and Technology Park, covering an area of more than 50,000 square meters. The company has more than 450 employees, and the proportion of professional and technical personnel exceeds 70%, including doctors and master students 10. All managers of the company have bachelor degree or above. The company's employees are in their prime of life, with an average age of under 35 and rich working experience in the industry. Yuheng Pharmaceutical Co., Ltd. is a "high-tech enterprise" recognized by the Heilongjiang provincial government and the first batch of key enterprises in the new pharmaceutical industrial base of the National Torch Plan recognized by the Ministry of Science and Technology. At present, the company has eight automatic production lines of small water injection, freeze-dried powder injection, cephalosporin freeze-dried powder injection, capsules, tablets, suppositories, powder injection filling and tumor drugs that have passed the national GMP certification, with an annual output of 200 million tablets, 48 million capsules, 40 million water injections and 40 million freeze-dried powder injections. At present, the company has listed 34 specifications of products, including Songmeile (Lugua Polypeptide Injection), and many products have entered the national basic medical and industrial injury insurance drug list. The leading product "Songmeile" injection (Lugua polypeptide injection) has become a national patent protection variety. Yuheng Pharmaceutical's business strategy in China pharmaceutical industry presents five obvious advantages: clear development goals, strong research and development capabilities, strict quality control, excellent market operation management and excellent reputation.

In 2004, all the production lines of Yuheng Pharmaceutical passed the GMP certification of the US Food and Drug Administration. More than 20 core brands developed by the company sell well all over the country.

In 2005, the annual sales of Yuheng Pharmaceutical exceeded 6,543.8 billion yuan.

In 2006, Yuheng Pharmaceutical developed by going up one flight of stairs, won the first overseas venture capital and completed the company reorganization. Yuheng Pharmaceutical has become a wholly foreign-owned enterprise, providing a platform for overseas financing and listing.

In 2006, the annual sales of Yuheng Pharmaceutical exceeded1.800 million yuan.

In 2007, Yuheng Pharmaceutical's annual sales exceeded 280 million yuan.

In 2008, Yuheng Pharmaceutical's annual sales exceeded 380 million yuan.

The Assets Operation Department of Harbin Development and Reform Commission approved it specially, and the Harbin Municipal Government gave Harbin Yuheng Pharmaceutical Co., Ltd. 6,543.8+0,000 yuan as a special subsidy for the listing of enterprises.

In order to encourage and support enterprises to go public for financing, Harbin Municipal Government issued "Several Opinions of Harbin Municipal People's Government on Further Promoting the Development of Financial Industry" in June, 2008, which clearly stipulated that the newly listed enterprises should be given a subsidy of 6.5438+0.00 million yuan, and the executives of listed enterprises should be given a reward of 6.5438+0.00 million yuan. Harbin Yuheng Pharmaceutical Co., Ltd. is an enterprise to be listed in Harbin.

In late September, 2008, this enterprise reported to the CSRC for listing, and in May, 5438+ 10, it got the acceptance letter of the application materials of the CSRC for listing, waiting for the audit of the audit committee organized by the CSRC. This is a major breakthrough for Harbin enterprises to go public in China since 2000.